Table 3. Risk assessment of PCa according to clinical and histological criteria, so called CAPRA (Cancer of the Prostate Risk Assessment) score (e8).

Variable	Range	Points
PSA ng/mL	2.0–6.0	0
	6.1–10.0	1
	10.1–20.0	2
	20.1–30.0	3
	> 30	4
Gleason score	1–3 / 1–3	0
	1–3 / 4–5	1
	4–5 / 1–5	3
Category of primary tumor	cT1 / cT2	0
	cT3a	1
Positive biopsies	<34 %	0
	≥ 34 %	1
Age	<50 years	0
	≥ 50 years	1

The CAPRA score assigns points to the patient’s age, PSA value, Gleason score, local tumor spread (cT), and proportion of tumor mass in the biopsy specimen. In patients with a score of 0–2 points, active surveillance is possible; in those whose score is 3–4 points, local treatment with curative intent is indicated; and in those with a score of 5–6 points this curative measure is supported by adjuvant hormone therapy. 7–10 points require systemic androgen deprivation.